Blood News and Research

RSS

Novel device may speed up medical decision-making for critically injured trauma patients

A tool that surgeons use for monitoring a patient's blood level in physicians' offices may also save valuable minutes in medical decision-making for critically injured trauma patients, according to study results published in the January 2015 issue of the Journal of the American College of Surgeons.

30 Dec 2014

MagnaChip launches new bio-sensor research collaboration

MagnaChip Semiconductor Corporation, a Korea-based designer and manufacturer of analog and mixed-signal semiconductor products, today announced it has launched a research collaboration focused on developing innovative, cost-effective silicon magnetic bio-sensor technology capable of monitoring extremely rare cells in blood.

30 Dec 2014

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

Roche today announced that the U.S. Food and Drug Administration has provided an Emergency Use Authorization (EUA) for the LightMix Ebola Zaire rRT-PCR Test for use on patients with signs and symptoms of Ebola Zaire virus infection in conjunction with epidemiological risk factors, such as individuals traveling from West Africa.

From Roche Sequencing and Life Science 30 Dec 2014

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Negative health effects of severe obesity

The negative health effects of severe obesity are very well known and have been thoroughly documented, yet obesity levels in the United States continue to remain stubbornly high. Many of these repercussions are life threatening and include heart attack, stroke, and a greatly increased chance of developing cancer.

27 Dec 2014

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.

25 Dec 2014

Vermillion closes previously announced private placement with investors

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, announced today that the Company closed its previously announced private placement with investors including Oracle Investment Management, Jack W. Schuler, Birchview Fund LLC and several Vermillion directors. Total proceeds were $10.5 million, before offering expenses.

25 Dec 2014

RMG’s Simi Valley Diabetes Clinic offers free diabetes care for members

Regal Medical Group (RMG) today announced its Simi Valley Diabetes Clinic, offering free diabetes care for members, has helped more than 200 patients receive comprehensive, individualized, successful treatment.

25 Dec 2014

Novastem uses Stemedica's stem cell products to treat patient in ischemic stroke study

Novastem, a leader in regenerative medicine, announces the treatment of its first patient in its study for ischemic stroke at Clinica Santa Clarita.

25 Dec 2014

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.

25 Dec 2014

Health Canada monitors recall of Jetfuel Superburn containing undeclared drug substances

"Jetfuel Superburn" is being recalled after Health Canada tests confirmed it contains two undeclared amphetamine-like drug substances that pose serious health risks (beta-methylphenethylamine and phenylpropylmethylamine).

25 Dec 2014

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

A team of researchers led by Duke Cancer Institute has identified key events that prompt certain cancer cells to develop resistance to otherwise lethal therapies.

24 Dec 2014

Patent recognizes peptide that reduces tissue damage

A Kansas State University research team has received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue.

24 Dec 2014

Unauthorized weight loss product seized from two retail locations in southwest of Calgary

The unauthorized product "Hydro-Lean" was seized from two Calgary stores because the label indicates it contains a combination of ingredients that can cause serious health risks (ephedrine and caffeine).

23 Dec 2014

PTC begins rolling NDA submission for Translarna to treat nmDMD

PTC Therapeutics, Inc. today announced that it has commenced a rolling submission of a New Drug Application to the United States Food and Drug Administration for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

23 Dec 2014

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati Therapeutics, Inc. today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl.

23 Dec 2014

EMA validates Synageva's sebelipase alfa MAA for LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders, today announced validation by the European Medicines Agency of the Marketing Authorization Application for sebelipase alfa for LAL Deficiency.

23 Dec 2014

CorMedix signs Neutrolin sales/distribution agreement with Arabian Trade House

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, announced today the first signed Middle East sales/distribution agreement for lead product Neutrolin with distributor Arabian Trade House in the Kingdom of Saudi Arabia.

23 Dec 2014

Shandong Taibang Biological Products earns GMP certification for new production facility

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.

23 Dec 2014

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

Blood News and Research

Novel device may speed up medical decision-making for critically injured trauma patients

MagnaChip launches new bio-sensor research collaboration

FDA provides Emergency Use Authorization for Roche's LightMix Ebola Zaire rRT-PCR Test

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Negative health effects of severe obesity

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

Vermillion closes previously announced private placement with investors

RMG’s Simi Valley Diabetes Clinic offers free diabetes care for members

Novastem uses Stemedica's stem cell products to treat patient in ischemic stroke study

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Health Canada monitors recall of Jetfuel Superburn containing undeclared drug substances

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

Patent recognizes peptide that reduces tissue damage

Unauthorized weight loss product seized from two retail locations in southwest of Calgary

PTC begins rolling NDA submission for Translarna to treat nmDMD

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

EMA validates Synageva's sebelipase alfa MAA for LAL Deficiency

CorMedix signs Neutrolin sales/distribution agreement with Arabian Trade House

Shandong Taibang Biological Products earns GMP certification for new production facility

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Latest News